SDHA and graft versus host disease: SDHA is regarded as a new target to mitigate T cell-mediated intestinal diseases including alloimmune gastrointestinal graft versus host disease (GI-GVHD), autoimmune inflammatory bowel disease (IBD), and iatrogenic CTLA-4Ig ICB-mediated colitis (66) because this reduction in SDHA caused an enhanced sensitivity of the intestinal epithelial cells (IECs) to T cell-mediated cytotoxicity (67, 68).